Marina Biotech makes organisational changes

Creates the position of executive vice president of r&d

Marina Biotech, a US nucleic acid-based drug discovery and development firm, has made some organisational changes.

Richard Ho has joined the firm in the newly created position of executive vice president, Research and Development.

In addition, Philip Ranker has become interim chief financial officer, replacing Peter Garcia who has resigned from the role to pursue other opportunities.

Barry Polisky has moved from chief scientific officer to distinguished scientist and has become chairman of the firm's Scientific Advisory Panel and Michael Templin has been promoted to the newly created position of senior vice president and chief technology officer.

Finally, Alan Dunton has joined the firm as consulting chief medical officer.

Marina Biotech’s goal is to improve human health through the development of RNAi and RNA-based compounds and drug delivery technologies.

You may also like

Research & Development

Drug licensing deals in 2010

Big pharma companies have been busy filling the yawning gaps in their product pipelines by licensing drugs developed by smaller biotechnology firms. Dr Sarah Houlton outlines a selection of the deals done this year
Research & Development

Marina Biotech acquires RNA assets of Novosom

Buys patent rights to Smarticles technology
Research & Development

Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform

Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Manufacturing

L.B. Bohle hosts successful continuous manufacturing workshop in Brazil

Focus on continuous wet granulation and drying for research, development and small-scale production
Manufacturing

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development

Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
Research & Development

Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption

A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
Manufacturing

Degasser for volatile and aggressive solvents

Biotech Fluidics announce the DEGASi Integration HFIP - a high-performance online system designed to efficiently degas even the toughest solvents. This unique degasser is fully compatible with a wide range of volatile and aggressive liquids including Hexafluoroisopropanol (HFIP) and silanes but can also manage all other solvents used for GPC/SEC and HPLC
Subscribe now